ReviewCureus2025

Impact of Glucagon-Like Peptide-1 Agonists on Hepatocellular Carcinoma Risk and Management in Type 2 Diabetes Mellitus: A Scoping Review.

Bassam Tungekar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.